IBC-Ab002 Antibody
A novel anti-PD-L1 antibody tailored specifically to treat neurodegenerative diseases
IBC-Ab002 is ImmunoBrain’s lead investigational therapy – a fully human anti-PD-L1 monoclonal antibody engineered with a short half-life and no Fc effector cytotoxic activity, enabling controlled, transient, intermittent systemic immune activation in chronic neurodegenerative disease settings. IBC-Ab002 works by temporarily releasing a natural ‘brake’ on the systemic immune system, activating peripheral responses that help restore the immune system’s ability to support the brain. It facilitates the trafficking of immune-regulating and repairing cells to the brain, where they help resolve inflammation and support synaptic and neuronal function, addressing a key driver of disease progression.
Intermittent dosing, approximately every three months, allows cycles of activation followed by resolution, aligning with the underlying biology and differentiating IBC-Ab002 from oncology checkpoint inhibitors. This is a deliberate design choice: short half-life and no Fc effector cytotoxic activity enable controlled immune activation while minimizing prolonged systemic exposure.
ImmunoBrain therapeutic approach with IBC-Ab002
By stimulating a peripheral immune pathway that can be activated regardless of etiology, this approach could also be potentially beneficial in other neurodegenerative diseases (e.g., Parkinson’s disease, Huntington’s disease, and other forms of age-related dementia) as well as age-related diseases outside of neurodegeneration.
